MedPath

Feasibility of Omega-3 Supplementation for Children With Language Impairments

Not Applicable
Terminated
Conditions
Language Impairment
Interventions
Dietary Supplement: Placebo
Dietary Supplement: Omega-3
Registration Number
NCT01640106
Lead Sponsor
Shuvo Ghosh
Brief Summary

The primary objective of this study is to obtain preliminary (pilot) data regarding the feasibility of using dietary omega-3 supplementation in children with significant delays in language skills; a related secondary objective is to compare adherence to a dosage schedule of two easy-to-take formulations. A tertiary objective of this study is to collect preliminary (pilot) data pre- and post-supplementation to identify potential improvement of skills in a specific area of language development.

Detailed Description

HYPOTHESIS Hypothesis 1: Children with early developmental impairment in language will successfully take daily omega-3 fatty acid supplementation for a well-defined period of time (3 months); Hypothesis 2: Children with early developmental impairment will better adhere to administration of a small quantity of slightly fishy-tasting oil than to a large quantity of sweet-tasting paste; Hypothesis 3: A 3 month period of daily omega-3 supplementation will produce some improvement in fast-mapping language skills (a dynamic vocabulary learning skill that has been shown to rapidly improve after exposure to beneficial intervention).

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
8
Inclusion Criteria
  • children in the chronological age range of 24 to 42 months at the time of initial assessment
  • diagnosis of expressive, receptive or mixed language impairment (LI) by a certified Speech-Language Pathologist (S-LP)
  • ability to take daily omega-3 supplementation (with caregiver assistance)
Exclusion Criteria
  • children with any organic disease processes or genetic syndromes, or known developmental disorders such as autism that may present with language impairment
  • children with hearing impairment
  • children who take any non-standard dietary supplements (i.e., apart from multi-vitamins), particularly any omega-3 FA, prior to starting the study
  • children whose parents do not have an adequate understanding of English or French

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ControlPlaceboPlacebo is a paste of non-omega-3 (plant based) oil with a taste/flavour identical to intervention paste
Omega-3Omega-3Treatment arm, using the omega-3 product (fish oil/paste)
Primary Outcome Measures
NameTimeMethod
Change over 3 months in learning assessed by a fast-mapping taskAssessed at time of diagnosis and 3 months after intervention

A simple "fast-mapping" task, which is a measure of language learning used widely in linguistics research, will be performed in the pre and post-intervention period. We will present a list of non-words selected with only early-developing sounds to ensure that they are within the repertoire of developmentally impaired children. Scores are calculated in terms of number of items successfully completed. An initial and final assessment of dynamic language learning will be done as an addendum to scores on standardized language tests that establish a language impairment diagnosis.

Secondary Outcome Measures
NameTimeMethod
Feasibility of fish oil vs. chewable Concordix pasteGiven for 3 months as intervention

In order to estimate the relative success of administering paste vs. oil in relation to omega-3 vs. placebo, a repeated measures ANOVA will be used to test for significant differences. The primary measure will be parental report as "easy" vs. "difficult" to administer, and the analysis will be run as Between group (paste vs. oil) by Treatment arm (omega-3 vs. placebo) by Adminstration success (easy vs. difficult).

Trial Locations

Locations (1)

McGill University/Montreal Children's Hospital

🇨🇦

Montreal, Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath